

Column A—What information is requested?	Column B—put data specific to the nominated substance
Has the bulk drug substance been used previously to compound drug product(s)?	Describe previous uses of the bulk drug substance in compounding.
Is there any other relevant information?	Provide any other information you would like FDA to consider in evaluating the nomination.

Interested persons may submit either electronic nominations to <http://www.regulations.gov> or written nominations to the Division of Dockets Management (see **ADDRESSES**). It is only necessary to send one set of nominations. Identify nominations with the docket number found in the brackets in the heading of this document. Received nominations may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at <http://www.regulations.gov>.

Dated: June 25, 2014.

Leslie Kux,

Assistant Commissioner for Policy.

[FR Doc. 2014–15373 Filed 7–1–14; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Statement of Organization, Functions and Delegations of Authority

This notice amends Part R of the Statement of Organization, Functions and Delegations of Authority of the Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA) (60 FR 56605, as amended November 6, 1995; 67 FR 46519, as amended June 11, 2008; 73 FR 33099, as amended September 30, 2009, 78 FR 50227, as last amended January 24, 2013, 78 FR 7436). This Order of Succession supersedes the Order of Succession for the Administrator, HRSA, published at 78 FR 7436, February 1, 2013.

This notice deletes the Bureau of Health Professions; the Bureau of Clinician Recruitment and Services; and Regional Division Directors from the order of succession, and adds the Bureau of Health Workforce and Regional Administrators to HRSA’s hierarchy affecting the Order of Succession. This notice reflects the new Order of Succession for HRSA.

Section R–30, Order of Succession

During the absence or disability of the Administrator, or in the event of a vacancy in the office, the officials

designated below shall act as Administrator in the order in which they are listed:

1. Deputy Administrator;
2. Chief Operating Officer;
3. Associate Administrator, Bureau of Primary Health Care;
4. Associate Administrator, Bureau of Health Workforce;
5. Associate Administrator, HIV/AIDS Bureau;
6. Associate Administrator, Maternal and Child Health Bureau;
7. Associate Administrator, Healthcare Systems Bureau;
8. Associate Administrator, Office of Regional Operations; and
9. HRSA Regional Administrators in the order in which they have received their permanent appointment as such.

Exceptions

(a) No official listed in this section who is serving in acting or temporary capacity shall, by virtue of so serving, act as Administrator pursuant to this section.

(b) Notwithstanding the provisions of this section, during a planned period of absence, the Administrator retains the discretion to specify a different order of succession.

Section R–40, Delegations of Authority

All delegations of authority and re-delegations of authority made to HRSA officials that were in effect immediately prior to this action, and that are consistent with this action, shall continue in effect pending further re-delegation, pending further re-delegation, provided they are consistent with this action.

This document is effective upon date of signature.

Dated: June 25, 2014.

Mary K. Wakefield,

Administrator.

[FR Doc. 2014–15498 Filed 7–1–14; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Submission for OMB Review; 30-Day Comment Request; Population Assessment of Tobacco and Health (PATH) Study

SUMMARY: Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institute on Drug Abuse (NIDA), the National Institutes of Health (NIH), has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. This proposed information collection was previously published in the **Federal Register** on February 6, 2014, pages 7206–7207, and allowed 60-days for public comment. One public comment was received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, OIRA_Submission@omb.eop.gov or by fax to 202–395–6974, Attention: NIH Desk Officer.

Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project contact: Kevin P. Conway, Ph.D., Deputy Director, Division of Epidemiology, Services, and Prevention Research, National Institute on Drug Abuse, 6001 Executive Boulevard., Room 5185; or call non-toll-free number (301)-443–8755; or Email your request,

including your address to: PATHprojectofficer@mail.nih.gov. Formal requests for additional plans and instruments must be requested in writing.

Proposed Collection: Population Assessment of Tobacco and Health (PATH) Study—Second Wave of Data Collection—0925–0664—Revision—National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), in partnership with the Food and Drug Administration (FDA).

Need and Use of Information Collection: This is a revision request (OMB 0925–0664, expires 11/30/2015) for the Population Assessment of Tobacco and Health (PATH) Study to conduct the second wave of data collection. The PATH Study is a large

national longitudinal cohort study on tobacco use behavior and health among the U.S. household population of adults age 18 and older and youth ages 12 to 17. The PATH Study conducts annual interviews and collects biospecimens from adults to help inform the development, implementation, and evaluation of tobacco-product regulations by FDA in meeting its mission under the Family Smoking Prevention and Tobacco Control Act (TCA) to regulate tobacco products, including tobacco-product advertising, labeling, marketing, constituents, ingredients, and additives. The longitudinal design of the PATH Study enables it to measure and report within-person changes and between-person differences in tobacco product use

behaviors and health effects within the cohort over time. These data will help to inform regulatory decisions and actions by FDA.

OMB approval is requested for 3 years. There are no capital, operating, or maintenance costs to report. There are no costs to respondents other than their time. The total estimated annualized burden hours are 56,939. Factors accounting for the difference between the baseline and Wave 2 total hours include the following: (1) Wave 2 does not have a screening phase; (2) as indicated in Supporting Statement B, a 86 percent response rate for adult interviews and a 90 percent response rate for youth interviews are projected for Wave 2; and (3) fewer biological samples will be collected in Wave 2.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent and instrument	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response	Estimated total annual burden hours requested
Adults—Extended Interview	* 27,113	1	1	27,113
Adults—Baseline youth respondents who age into adult cohort—Consent for Extended Interview	2,295	1	2/60	77
Adults—Baseline youth respondents who age into adult cohort—Extended Interview	* 1,990	1	68/60	2,255
Adults—Baseline youth respondents who age into the adult cohort—Consent for Biological Samples	1,990	1	4/60	133
Adults—Biospecimen Collection: Urine	11,373	1	10/60	1,896
Adults—Biospecimen Collection: Blood	896	1	18/60	269
Adults—Tobacco Use Form	12,269	1	4/60	818
Adults—Follow-up/Tracking Participant Information Form	33,615	2	8/60	8,964
Youth—Extended Interview	** 10,537	1	32/60	5,620
Youth—Shadow youth who age into youth cohort—Assent for Extended Interview	2,338	1	2/60	78
Youth—Shadow youth who age into youth cohort—Extended Interview	** 2,105	1	42/60	1,474
Parent Interview	10,748	1	14/60	2,508
Parents of Shadow youth who age into youth cohort—Parent Permission and Consent for Parent Interview	2,338	1	2/60	78
Parents of Shadow youth who age into youth cohort—Parent Interview	2,147	1	17/60	608
Parents of youth—Follow-up/Tracking Participant Information Form for Youth	14,165	2	8/60	3,777
Adults—Follow-up/Tracking Participant Information Form for sample Shadow youth (completed by parents)	4,772	2	8/60	1,273

* Estimated total number of adult extended interview respondents is 27,113 adults from Wave 1 + 1,990 youth from Wave 1 who turn 18 by Wave 2 = 29,103.

** Estimated total number of youth extended interview respondents is 10,537 youth from Wave 1 + 2,105 shadow youth who turn 12 by Wave 2 = 12,642.

Dated: June 25, 2014.
Genevieve R. deAlmeida,
Project Clearance Liaison, National Institute on Drug Abuse.
 [FR Doc. 2014–15584 Filed 7–1–14; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, Kidney Disease Ancillary Studies.